{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:54:18Z","timestamp":1777636458051,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/PR25498\/NER\/95\/1223\/2017"],"award-info":[{"award-number":["BT\/PR25498\/NER\/95\/1223\/2017"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Biochem Biotechnol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s12010-022-04111-3","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T06:02:37Z","timestamp":1662444157000},"page":"152-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Tracing the Anti-cancer Mechanism of Pleurotus osteratus by the Integrative Approach of Network Pharmacology and Experimental Studies"],"prefix":"10.1007","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9242-9597","authenticated-orcid":false,"given":"Singh","family":"Shreya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dulla Naveen","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3044-8706","authenticated-orcid":false,"given":"Debadatta","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5234-0021","authenticated-orcid":false,"given":"Gaurav Gopal","family":"Naik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9287-1836","authenticated-orcid":false,"given":"Santosh Kumar","family":"Guru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-3647","authenticated-orcid":false,"given":"Ashish Kumar","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6008-4571","authenticated-orcid":false,"given":"Senthil Raja","family":"Ayyannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2378-6179","authenticated-orcid":false,"given":"Alakh N.","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"issue":"10","key":"4111_CR1","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: An evolving paradigm. Nature Reviews Cancer, 13(10), 714\u2013726. https:\/\/doi.org\/10.1038\/nrc3599","journal-title":"Nature Reviews Cancer"},{"issue":"11","key":"4111_CR2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","volume":"4","author":"AL Hopkins","year":"2008","unstructured":"Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682\u2013690. https:\/\/doi.org\/10.1038\/nchembio.118","journal-title":"Nature Chemical Biology"},{"key":"4111_CR3","doi-asserted-by":"publisher","unstructured":"Kumar, D. N., Chaudhuri, A., Dehari, D., Shekher, A., Gupta, S. C., Majumdar, S., \u2026 Agrawal, A. K. (2022). Combination therapy comprising paclitaxel and 5-fluorouracil by using folic acid functionalized bovine milk exosomes improves the therapeutic efficacy against breast cancer. Life, 12(8). https:\/\/doi.org\/10.3390\/life12081143","DOI":"10.3390\/life12081143"},{"key":"4111_CR4","doi-asserted-by":"publisher","unstructured":"Kumar, D. N., Chaudhuri, A., Aqil, F., Dehari, D., Munagala, R., Singh, S., \u2026 Agrawal, A. K. (2022). Exosomes as emerging drug delivery and diagnostic modality for breast cancer: Recent advances in isolation and application. Cancers, 14(6). https:\/\/doi.org\/10.3390\/cancers14061435","DOI":"10.3390\/cancers14061435"},{"issue":"3","key":"4111_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10030659","volume":"10","author":"HYK Yip","year":"2021","unstructured":"Yip, H. Y. K., & Papa, A. (2021). Signaling pathways in cancer: Therapeutic targets, combinatorial treatments, and new developments. Cells, 10(3), 1\u201330. https:\/\/doi.org\/10.3390\/cells10030659","journal-title":"Cells"},{"issue":"5","key":"4111_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph15050572","volume":"15","author":"F Noor","year":"2022","unstructured":"Noor, F., Qamar, M. T. U., Ashfaq, U. A., Albutti, A., Alwashmi, A. S. S., & Aljasir, M. A. (2022). Network pharmacology approach for medicinal plants: Review and assessment. Pharmaceuticals, 15(5), 1\u201333. https:\/\/doi.org\/10.3390\/ph15050572","journal-title":"Pharmaceuticals"},{"issue":"2","key":"4111_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrd4510","volume":"14","author":"AL Harvey","year":"2015","unstructured":"Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015). The re-emergence of natural products for drug discovery in the genomics era. Nature Reviews Drug Discovery, 14(2), 111\u2013129. https:\/\/doi.org\/10.1038\/nrd4510","journal-title":"Nature Reviews Drug Discovery"},{"key":"4111_CR8","doi-asserted-by":"publisher","unstructured":"Sun, Y., Sheng, Z., Ma, C., Tang, K., Zhu, R., Wu, Z., \u2026 Cao, Z. (2015). Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer. Nature Communications, 6(1), 8481. https:\/\/doi.org\/10.1038\/ncomms9481","DOI":"10.1038\/ncomms9481"},{"key":"4111_CR9","doi-asserted-by":"publisher","DOI":"10.2174\/1570180819666220518100010","author":"S Shreya","year":"2022","unstructured":"Shreya, S., Jain, S. K., Guru, S. K., & Sahu, A. N. (2022). Anti-cancer potential of Pleurotus mushroom: Detailed insight on the potential bioactive molecules, invitro-invivo studies, and formulation. Letters in Drug Design & Discovery. https:\/\/doi.org\/10.2174\/1570180819666220518100010","journal-title":"Letters in Drug Design & Discovery"},{"key":"4111_CR10","doi-asserted-by":"publisher","unstructured":"Golak-siwulska, I., Ka\u0142u\u017cewicz, A., & Spi\u017cewski, T. (2018). Bioactive compounds and medicinal properties of Oyster mushrooms (Pleurotus sp.), 30(2), 191\u2013201. https:\/\/doi.org\/10.2478\/fhort-2018-0012","DOI":"10.2478\/fhort-2018-0012"},{"issue":"1","key":"4111_CR11","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7(1), 42717. https:\/\/doi.org\/10.1038\/srep42717","journal-title":"Scientific Reports"},{"issue":"W1","key":"4111_CR12","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","volume":"47","author":"A Daina","year":"2019","unstructured":"Daina, A., Michielin, O., & Zoete, V. (2019). SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Research, 47(W1), W357\u2013W364. https:\/\/doi.org\/10.1093\/nar\/gkz382","journal-title":"Nucleic Acids Research"},{"key":"4111_CR13","doi-asserted-by":"publisher","unstructured":"Rappaport, N., Twik, M., Plaschkes, I., Nudel, R., Iny Stein, T., Levitt, J., \u2026 Lancet, D. (2017). MalaCards: An amalgamated human disease compendium with diverse clinical and genetic annotation and structured search. Nucleic Acids Research, 45(D1), D877\u2013D887. https:\/\/doi.org\/10.1093\/nar\/gkw1012","DOI":"10.1093\/nar\/gkw1012"},{"key":"4111_CR14","doi-asserted-by":"publisher","unstructured":"Pi\u00f1ero, J., Bravo, \u00c0., Queralt-Rosinach, N., Guti\u00e9rrez-Sacrist\u00e1n, A., Deu-Pons, J., Centeno, E., \u2026 Furlong, L. I. (2017). DisGeNET: A comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Research, 45(D1), D833\u2013D839. https:\/\/doi.org\/10.1093\/nar\/gkw943","DOI":"10.1093\/nar\/gkw943"},{"key":"4111_CR15","doi-asserted-by":"publisher","unstructured":"Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., \u2026 von Mering, C. (2015). STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Research, 43(Database issue), D447\u201352. https:\/\/doi.org\/10.1093\/nar\/gku1003","DOI":"10.1093\/nar\/gku1003"},{"issue":"22","key":"4111_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1101\/gr.1239303.metabolite","volume":"13","author":"P Shannon","year":"1971","unstructured":"Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (1971). Cytoscape: A software environment for integrated models. Genome Research, 13(22), 426. https:\/\/doi.org\/10.1101\/gr.1239303.metabolite","journal-title":"Genome Research"},{"issue":"8","key":"4111_CR17","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/bioinformatics\/btz931","volume":"36","author":"SX Ge","year":"2020","unstructured":"Ge, S. X., Jung, D., & Yao, R. (2020). ShinyGO: A graphical gene-set enrichment tool for animals and plants. Bioinformatics, 36(8), 2628\u20132629. https:\/\/doi.org\/10.1093\/bioinformatics\/btz931","journal-title":"Bioinformatics"},{"issue":"16","key":"4111_CR18","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M., Ruth, H., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). Software news and updates AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785\u20132791. https:\/\/doi.org\/10.1002\/jcc.21256","journal-title":"Journal of Computational Chemistry"},{"key":"4111_CR19","doi-asserted-by":"publisher","unstructured":"Guru, S. K., Pathania, A. S., Kumar, S., Ramesh, D., Kumar, M., Rana, S., \u2026 Bhushan, S. (2015). Secalonic acid-D represses HIF1\u03b1\/VEGF-mediated angiogenesis by regulating the Akt\/mTOR\/p70S6K signaling cascade. Cancer Research, 75(14), 2886\u20132896. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2312","DOI":"10.1158\/0008-5472.CAN-14-2312"},{"key":"4111_CR20","doi-asserted-by":"publisher","unstructured":"OECD. (2002). Test No. 423: Acute oral toxicity \u2013 Acute toxic class method. Oecd Guideline for Testing of Chemicals, (December), 1\u201314. https:\/\/doi.org\/10.1787\/9789264071001-en","DOI":"10.1787\/9789264071001-en"},{"key":"4111_CR21","doi-asserted-by":"publisher","unstructured":"Saneja, A., Kumar, R., Singh, A., Dhar Dubey, R., Mintoo, M. J., Singh, G., \u2026 Gupta, P. N. (2017). Development and evaluation of long-circulating nanoparticles loaded with betulinic acid for improved anti-tumor efficacy. International Journal of Pharmaceutics (Vol. 531). Elsevier B.V. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.08.076","DOI":"10.1016\/j.ijpharm.2017.08.076"},{"issue":"5","key":"4111_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrc3920","volume":"15","author":"CX Ma","year":"2015","unstructured":"Ma, C. X., Reinert, T., Chmielewska, I., & Ellis, M. J. (2015). Mechanisms of aromatase inhibitor resistance. Nature Reviews Cancer, 15(5), 261\u2013275. https:\/\/doi.org\/10.1038\/nrc3920","journal-title":"Nature Reviews Cancer"},{"issue":"2","key":"4111_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.bcp.2011.03.031","volume":"82","author":"SE Wardell","year":"2011","unstructured":"Wardell, S. E., Marks, J. R., & McDonnell, D. P. (2011). The turnover of estrogen receptor \u03b1 by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochemical Pharmacology, 82(2), 122\u2013130. https:\/\/doi.org\/10.1016\/j.bcp.2011.03.031","journal-title":"Biochemical Pharmacology"},{"issue":"2","key":"4111_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0304-3835(94)90194-5","volume":"81","author":"\u00c5 Borg","year":"1994","unstructured":"Borg, \u00c5., Baldetorp, B., Fern\u00f6, M., Killander, D., Olsson, H., Ryden, S., & Sigurdsson, H. (1994). ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Letters, 81(2), 137\u2013144. https:\/\/doi.org\/10.1016\/0304-3835(94)90194-5","journal-title":"Cancer Letters"},{"issue":"9","key":"4111_CR25","first-page":"1643","volume":"3","author":"JC Newby","year":"1997","unstructured":"Newby, J. C., Johnston, S. R., Smith, I. E., & Dowsett, M. (1997). Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 3(9), 1643\u20131651.","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"issue":"6","key":"4111_CR26","first-page":"608","volume":"4","author":"M Luo","year":"2014","unstructured":"Luo, M., & Fu, L.-W. (2014). Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors. American Journal of Cancer Research, 4(6), 608\u2013628.","journal-title":"American Journal of Cancer Research"},{"key":"4111_CR27","doi-asserted-by":"publisher","unstructured":"Ludovini, V., Bianconi, F., Pistola, L., Chiari, R., Minotti, V., Colella, R., \u2026 Crin\u00f2, L. (2011). Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology, 6(4), 707\u2013715. https:\/\/doi.org\/10.1097\/JTO.0b013e31820a3a6b","DOI":"10.1097\/JTO.0b013e31820a3a6b"}],"container-title":["Applied Biochemistry and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-022-04111-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12010-022-04111-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-022-04111-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T16:08:21Z","timestamp":1673626101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12010-022-04111-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["4111"],"URL":"https:\/\/doi.org\/10.1007\/s12010-022-04111-3","relation":{},"ISSN":["0273-2289","1559-0291"],"issn-type":[{"value":"0273-2289","type":"print"},{"value":"1559-0291","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"28 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study on animals was approved by the Institutional Animal Ethics Committee approval (Protocol no. Dean\/2021\/IAEC\/2553).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}